Immunotherapy for head and neck squamous cell carcinoma

被引：19

作者：

Li, Qiao ^{[1
]}

Prince, Mark E. P. ^{[1
]}

Moyer, Jeffrey S. ^{[1
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

来源：

ORAL ONCOLOGY | 2015年 / 51卷 / 04期

关键词：

Monoclonal antibody therapy; Cytokine therapy; Cancer vaccines; T cell-based therapy; Cancer stem cells; REGULATORY T-CELLS; ANTIGEN-PROCESSING MACHINERY; ENDOTHELIAL GROWTH-FACTOR; CANCER STEM-CELLS; CHEMOTHERAPY PLUS CETUXIMAB; HUMAN DENDRITIC CELLS; CLASS-I ANTIGEN; DOWN-REGULATION; NATURAL-KILLER; PHASE-I;

D O I：

10.1016/j.oraloncology.2014.12.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: To review the current state of immunotherapy of head and neck squamous cell carcinoma. Materials and Methods: Review of the literature with emphasis on clinical trial data. Results: Patients with head and neck squamous cell carcinoma (HNSCC) have long been known to be immunosuppressed. This impairment of the immune system is believed, at least in part, to underlie the poor outcomes in this patient population. Modulating the immune system to improve cancer outcomes is an attractive concept in this difficult to treat population. Conclusion: New studies have started to unravel the mechanisms of immunosuppression and new therapies are being developed to exploit this new information. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：299 / 304

页数：6

共 105 条

[1] Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[2]

Almand B, 2000, CLIN CANCER RES, V6, P1755

[3] Metronomics: towards personalized chemotherapy? [J].

Andre, Nicolas ;

Carre, Manon ;

Pasquier, Eddy .

NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (07) :413-431

[4] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[5] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck [J].

Argiris, A. ;

Kotsakis, A. P. ;

Hoang, T. ;

Worden, F. P. ;

Savvides, P. ;

Gibson, M. K. ;

Gyanchandani, R. ;

Blumenschein, G. R., Jr. ;

Chen, H. X. ;

Grandis, J. R. ;

Harari, P. M. ;

Kies, M. S. ;

Kim, S. .

ANNALS OF ONCOLOGY, 2013, 24 (01) :220-225

[6] Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial [J].

Argiris, Athanassios ;

Ghebremichael, Musie ;

Gilbert, Jill ;

Lee, Ju-Whei ;

Sachidanandam, Kamakshi ;

Kolesar, Jill M. ;

Burtness, Barbara ;

Forastiere, Arlene A. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) :1405-1414

[7] HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis [J].

Bandoh, Nobuyuki ;

Ogino, Takeshi ;

Katayama, Akihiro ;

Takahara, Miki ;

Katada, Akihiro ;

Hayashi, Tatsuya ;

Harabuchi, Yasuaki .

ONCOLOGY REPORTS, 2010, 23 (04) :933-939

[8] Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model [J].

Banissi, Claire ;

Ghiringhelli, Francois ;

Chen, Lin ;

Carpentier, Antoine F. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (10) :1627-1634

[9] Nimotuzumab with chemoradiation confers survival advantage in treatment naive head and neck tumors overexpressing EGFR [J].

Basavaraj, Chetana ;

Sierra, Patricia ;

Shivu, Jatteppanavar ;

Melarkode, Ramakrishnan ;

Montero, Enrique ;

Nair, Pradip .

CANCER BIOLOGY & THERAPY, 2010, 10 (07) :673-681

[10] Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer [J].

Bauernhofer, T ;

Kuss, I ;

Henderson, B ;

Baum, AS ;

Whiteside, TL .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (01) :119-124

← 1 2 3 4 5 6 7 8 9 10 →